Does the media refer more to COGT or ROIV?

In the previous week, Roivant Sciences had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 12 mentions for Roivant Sciences and 9 mentions for Cogent Biosciences. Roivant Sciences' average media sentiment score of 1.59 beat Cogent Biosciences' score of 0.69 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is INSM or COGT more profitable?

Cogent Biosciences has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Cogent Biosciences' return on equity of -104.27% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Cogent Biosciences N/A -104.27% -54.64%

Does the media refer more to INSM or COGT?

In the previous week, Insmed had 16 more articles in the media than Cogent Biosciences. MarketBeat recorded 25 mentions for Insmed and 9 mentions for Cogent Biosciences. Insmed's average media sentiment score of 1.22 beat Cogent Biosciences' score of 0.69 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 18 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COGT or MRNA?

In the previous week, Moderna had 10 more articles in the media than Cogent Biosciences. MarketBeat recorded 19 mentions for Moderna and 9 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.69 beat Moderna's score of 0.57 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to COGT or GMAB?

In the previous week, Cogent Biosciences had 5 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Cogent Biosciences and 4 mentions for Genmab A/S. Cogent Biosciences' average media sentiment score of 0.69 beat Genmab A/S's score of 0.47 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cogent Biosciences (COGT) Competitors

$33.10 +0.48 (+1.47%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$33.50 +0.40 (+1.21%)

As of 06/12/2026 05:48 PM Eastern

Compare

COGT vs. ROIV, INSM, MRNA, VTRS, and GMAB

Should you buy Cogent Biosciences stock or one of its competitors? MarketBeat compares Cogent Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cogent Biosciences include Roivant Sciences (ROIV), Insmed (INSM), Moderna (MRNA), Viatris (VTRS), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry.

How does Cogent Biosciences compare to Roivant Sciences?

Cogent Biosciences (NASDAQ:COGT) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Cogent Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Cogent Biosciences presently has a consensus price target of $43.73, indicating a potential upside of 32.11%. Roivant Sciences has a consensus price target of $33.59, indicating a potential upside of 11.82%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cogent Biosciences is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Roivant Sciences had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 12 mentions for Roivant Sciences and 9 mentions for Cogent Biosciences. Roivant Sciences' average media sentiment score of 1.59 beat Cogent Biosciences' score of 0.69 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Roivant Sciences has higher revenue and earnings than Cogent Biosciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Roivant Sciences	$8.26M	2,615.84	-$299.77M	-$0.60	N/A

Cogent Biosciences has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

64.8% of Roivant Sciences shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Roivant Sciences beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Insmed?

Insmed (NASDAQ:INSM) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Cogent Biosciences has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	34.97	-$1.28B	-$5.75	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Insmed presently has a consensus target price of $212.50, indicating a potential upside of 117.17%. Cogent Biosciences has a consensus target price of $43.73, indicating a potential upside of 32.11%. Given Insmed's stronger consensus rating and higher possible upside, equities analysts plainly believe Insmed is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Cogent Biosciences has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Cogent Biosciences' return on equity of -104.27% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Cogent Biosciences	N/A	-104.27%	-54.64%

In the previous week, Insmed had 16 more articles in the media than Cogent Biosciences. MarketBeat recorded 25 mentions for Insmed and 9 mentions for Cogent Biosciences. Insmed's average media sentiment score of 1.22 beat Cogent Biosciences' score of 0.69 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	18 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Summary

Insmed beats Cogent Biosciences on 8 of the 14 factors compared between the two stocks.

How does Cogent Biosciences compare to Moderna?

Cogent Biosciences (NASDAQ:COGT) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Cogent Biosciences has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Moderna	-143.55%	-26.64%	-19.32%

In the previous week, Moderna had 10 more articles in the media than Cogent Biosciences. MarketBeat recorded 19 mentions for Moderna and 9 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.69 beat Moderna's score of 0.57 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Cogent Biosciences presently has a consensus price target of $43.73, indicating a potential upside of 32.11%. Moderna has a consensus price target of $36.60, indicating a potential downside of 26.67%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Cogent Biosciences is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Cogent Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

75.3% of Moderna shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cogent Biosciences has higher earnings, but lower revenue than Moderna. Cogent Biosciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Moderna	$1.94B	10.19	-$2.82B	-$8.15	N/A

Summary

Cogent Biosciences and Moderna tied by winning 8 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Viatris?

Cogent Biosciences (NASDAQ:COGT) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

79.9% of Viatris shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cogent Biosciences had 8 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Cogent Biosciences and 1 mentions for Viatris. Viatris' average media sentiment score of 1.87 beat Cogent Biosciences' score of 0.69 indicating that Viatris is being referred to more favorably in the news media.

Company	Overall Sentiment
Cogent Biosciences	Positive
Viatris	Very Positive

Cogent Biosciences has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Viatris	$14.30B	1.34	-$3.51B	-$0.26	N/A

Cogent Biosciences presently has a consensus price target of $43.73, indicating a potential upside of 32.11%. Viatris has a consensus price target of $17.50, indicating a potential upside of 6.19%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Cogent Biosciences is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Cogent Biosciences has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Viatris	-2.04%	19.04%	7.62%

Cogent Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

Cogent Biosciences beats Viatris on 9 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Genmab A/S?

Cogent Biosciences (NASDAQ:COGT) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Genmab A/S has a net margin of 21.05% compared to Cogent Biosciences' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Genmab A/S	21.05%	15.34%	8.94%

Cogent Biosciences currently has a consensus target price of $43.73, suggesting a potential upside of 32.11%. Genmab A/S has a consensus target price of $37.93, suggesting a potential upside of 51.23%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Cogent Biosciences had 5 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Cogent Biosciences and 4 mentions for Genmab A/S. Cogent Biosciences' average media sentiment score of 0.69 beat Genmab A/S's score of 0.47 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.1% of Genmab A/S shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cogent Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Genmab A/S	$3.72B	4.20	$963M	$1.32	19.00

Summary

Genmab A/S beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks.

Get Cogent Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COGT vs. The Competition

Export

Metric	Cogent Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.66B	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-15.25	19.82	24.21	24.42
Price / Sales	N/A	305.69	512.04	109.94
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	8.62	8.32	10.66	6.83
Net Income	-$328.94M	$23.94M	$3.57B	$337.67M
7 Day Performance	6.71%	3.53%	0.84%	2.68%
1 Month Performance	-3.19%	-2.55%	-0.34%	1.56%
1 Year Performance	367.51%	44.82%	25.40%	30.59%

Cogent Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COGT Cogent Biosciences	2.6664 of 5 stars	$33.10 +1.5%	$43.73 +32.1%	+367.5%	$5.66B	N/A	N/A	80	News Coverage
ROIV Roivant Sciences	2.2842 of 5 stars	$28.49 -0.3%	$33.59 +17.9%	+165.4%	$20.56B	$8.26M	N/A	860	Positive News
INSM Insmed	3.4261 of 5 stars	$94.17 -0.1%	$212.50 +125.7%	-0.9%	$20.42B	$606.42M	N/A	1,664	Positive News Analyst Forecast Options Volume
MRNA Moderna	1.312 of 5 stars	$47.60 +0.3%	$36.60 -23.1%	+87.1%	$18.82B	$1.94B	N/A	4,700
VTRS Viatris	3.2284 of 5 stars	$15.93 +0.3%	$17.50 +9.9%	+84.8%	$18.49B	$14.30B	N/A	30,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COGT) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cogent Biosciences (COGT) Competitors

COGT vs. ROIV, INSM, MRNA, VTRS, and GMAB

How does Cogent Biosciences compare to Roivant Sciences?

Summary

How does Cogent Biosciences compare to Insmed?

Summary

How does Cogent Biosciences compare to Moderna?

Summary

How does Cogent Biosciences compare to Viatris?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cogent Biosciences (COGT) Competitors

COGT vs. ROIV, INSM, MRNA, VTRS, and GMAB

How does Cogent Biosciences compare to Roivant Sciences?

Which has more volatility and risk, COGT or ROIV?

Do analysts prefer COGT or ROIV?

Does the media refer more to COGT or ROIV?

Which has preferable valuation & earnings, COGT or ROIV?

Is COGT or ROIV more profitable?

Do insiders & institutionals have more ownership in COGT or ROIV?

Summary

How does Cogent Biosciences compare to Insmed?

Which has preferable valuation & earnings, INSM or COGT?

Do analysts prefer INSM or COGT?

Is INSM or COGT more profitable?

Does the media refer more to INSM or COGT?

Which has more risk and volatility, INSM or COGT?

Summary

How does Cogent Biosciences compare to Moderna?

Is COGT or MRNA more profitable?

Does the media prefer COGT or MRNA?

Do analysts recommend COGT or MRNA?

Which has more risk & volatility, COGT or MRNA?

Do insiders & institutionals believe in COGT or MRNA?

Which has preferable earnings & valuation, COGT or MRNA?

Summary

How does Cogent Biosciences compare to Viatris?

Do insiders and institutionals have more ownership in COGT or VTRS?

Does the media prefer COGT or VTRS?

Which has stronger valuation & earnings, COGT or VTRS?

Do analysts prefer COGT or VTRS?

Is COGT or VTRS more profitable?

Which has more risk & volatility, COGT or VTRS?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Is COGT or GMAB more profitable?

Do analysts recommend COGT or GMAB?

Does the media refer more to COGT or GMAB?

Do institutionals & insiders hold more shares of COGT or GMAB?

Which has more volatility and risk, COGT or GMAB?

Which has preferable valuation & earnings, COGT or GMAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools